Revolution Medicines, Inc.
RVMD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $205,749 | $188,096 |
| Gross Profit | $0 | $0 | -$205,749 | -$188,096 |
| % Margin | – | – | – | – |
| R&D Expenses | $262,506 | $224,134 | $205,749 | $188,096 |
| G&A Expenses | $52,763 | $40,580 | $35,011 | $28,214 |
| SG&A Expenses | $52,763 | $40,580 | $35,011 | $28,214 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$205,749 | -$188,096 |
| Operating Expenses | $315,269 | $264,714 | $35,011 | $28,214 |
| Operating Income | -$315,269 | -$264,714 | -$240,760 | -$216,310 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $10,063 | $16,927 | $27,344 | $20,988 |
| Pre-Tax Income | -$305,206 | -$247,787 | -$213,416 | -$195,322 |
| Tax Expense | $0 | $0 | $0 | -$753 |
| Net Income | -$305,206 | -$247,787 | -$213,416 | -$194,569 |
| % Margin | – | – | – | – |
| EPS | -1.61 | -1.31 | -1.13 | -1.13 |
| % Growth | -22.9% | -15.9% | 0% | – |
| EPS Diluted | -1.61 | -1.31 | -1.13 | -1.13 |
| Weighted Avg Shares Out | 189,231 | 188,146 | 188,146 | 167,738 |
| Weighted Avg Shares Out Dil | 189,231 | 188,146 | 188,146 | 167,738 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,655 | $22,404 | $24,915 | $21,225 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,830 | $3,802 | $3,716 | $3,387 |
| EBITDA | -$302,376 | -$260,912 | -$237,044 | -$212,923 |
| % Margin | – | – | – | – |